AVITA Medical Stock

AVITA Medical EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of AVITA Medical (RCEL) as of Aug 8, 2026 is -56.00 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -42.35 M USD — a change of 32.24% (lower).

EBITDA

-56.00 MUSD

YoY

32.24%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of AVITA Medical is 2026 -56.00 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of AVITA Medical was 2025 -42.35 M USD. It decreases by 32.24% lower compared to the previous year.
Access this data via the Eulerpool API

AVITA Medical Stock analysis

What does AVITA Medical do? AVITA Medical Inc is a company in the field of regenerative medicine that focuses on the development and marketing of innovative therapy products for the treatment of burns, chronic wounds, and skin defects. The company was founded in 1998 and is headquartered in Valencia, California. AVITA Medical Inc began with research in the field of regenerative medicine at the University of Western Australia, where the company developed its patented technology known as ReNovaCell. This technology allows for the extraction and cultivation of cells from a small area of skin to create a solution that contains the patient's own skin tissue on a large scale. AVITA Medical Inc's business model is based on the development and marketing of regenerative therapy products based on ReNovaCell technology. The company focuses on commercializing products that enable fast, safe, and effective treatment of burns, chronic wounds, and skin defects. AVITA Medical Inc operates in two main segments: regenerative medicine and aesthetic medicine. In regenerative medicine, the company offers a wide range of products based on ReNovaCell technology, including ReCell, a unique autologous cell therapy for rapid burn treatment, Kelo-Cote, a silicone gel formulation for scar treatment, and therapy-complementary wound treatments. In aesthetic medicine, the company distributes a variety of products under the brand RestoreSkin, which focuses on improving skin health and aesthetic appearance, including pore refinement, pigment reduction, and wrinkle reduction. AVITA Medical Inc has established itself as a leading provider of regenerative therapy products. The company has a strong presence both in the US and internationally and is actively advocating for the advancement of regenerative medicine. By developing innovative products that enable fast and effective treatment of skin defects, AVITA Medical Inc will continue to be a key player in regenerative medicine in the future. AVITA Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AVITA Medical stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of AVITA Medical is -56.00 M USD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of AVITA Medical changed from -42.35 M USD to -56.00 M USD, representing a 32.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) AVITA Medical since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s AVITA Medical historically and in real time.

Access this data via the Eulerpool API

Income Statement — AVITA Medical

All Key Metrics — AVITA Medical